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Induction of cyclooxygenase-2 in human synovial cells by b2- tological disorders, including carpal tunnel syndrome,
microglobulin. chronic synovitis, and progressive bone destruction [5–
Background. Prostaglandins (PGs) are important mediators 8]. Although b2m plays an important role in the develop-of inflammation in arthritis. We evaluated the role of the cyclo-
ment of HAA, the precise molecular pathogenic mecha-oxygenase-2 (COX-2) enzyme, which regulates PG biosynthe-
nisms of these complications remain unknown.sis, in osteoarthropathy associated with hemodialysis-associ-
ated amyloidosis (HAA) by characterizing COX-2 expression Excessive production of prostaglandins (PGs) is asso-
in b2-microglobulin–treated human synovial cells. ciated with the development of major pathological pro-
Methods. We examined the effects of b2-microglobulin (b2m), cesses and plays a critical role in eliciting inflammationa major constituent protein of amyloid fibrils in HAA, on the
[9]. Cyclooxygenase (COX) is a key regulatory enzymeCOX-2 protein and mRNA expression in human synovial cells
in the biosynthesis of PGs [10, 11]. COX exists in twousing Western blot and reverse transcriptase-polymerase chain
reaction. forms [12, 13]. While COX-1 is present in most tissues
Results. b2m selectively increased the biosynthesis of COX-2 and is involved in the physiological production of PGs
protein and induction of COX-2 mRNA in a dose-dependent [14], COX-2 is almost undetectable under physiologicalmanner. Immunoabsorption of b2m–containing media by anti-
conditions in most tissues. Its expression is highly inducedb2m–specific antibody abrogated b2m–mediated COX-2 ex-
by proinflammatory agents such as cytokines and growthpression on synovial cells. On the other hand, dexamethasone
markedly suppressed the induction of COX-2 protein and factors [15–17]. Therefore, up-regulation of COX-2 is
mRNA in b2m–stimulated synovial cells. considered the mechanism through which cellular PG
Conclusions. Our results suggest that induction of COX-2
levels are elevated in inflammatory processes. Experi-expression by b2m may be an important component of the
mental evidence suggests the involvement of elevatedinflammatory process in hemodialysis-associated osteoarthro-
pathy. biosynthesis of PGs in the inflammatory process affecting
the synovial cells and articular destruction in inflamma-
tory joint diseases [18, 19]. For example, COX-2 is ex-
Amyloid arthritis has been described previously in pressed in human rheumatoid synovial tissues, and in-
patients with systemic amyloidosis such as immunoglob- flammatory cytokines induce the synthesis of COX-2
ulin light-chain–derived amyloidosis [1, 2]. Also, it is well mRNA and protein in cultured synovial cells [20].
known that amyloid protein induces the production of Interestingly, the clinical manifestations of HAA are
proteinases from synovial cells, which may contribute to similar to those of inflammatory joint diseases. Recent
articular destruction [3]. b2-microglobulin (b2m) is the studies suggest that b2m has biological functions in a
major constituent protein of amyloid fibrils in hemodial- variety of cells, including synovial cells and osteoblasts
ysis-associated amyloidosis (HAA) [4]. The main clinical [21–23]. This study was designed to assess the effects of
manifestations of this disease include a group of rheuma- b2m on the expression of COX-2 in human synovial cells.
Key words: amyloidosis, prostaglandin, dexamethasone, osteoarthrop- METHODSathy, hemodialysis.
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was subsequently diluted in experimental culture media. Rad protein assay kit (Bio-Rad, Hercules, CA, USA).
An identical amount of protein (50 mg) for each lysateb2m was analyzed by 14% sodium dodecyl sulfate-poly-
acrylamide gel under reducing conditions and migrated was subjected to 10% sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis. The fractionated proteinsas a single band (data not shown). No endotoxin was
detected (,0.18 EU/ml) under our experimental culture were transferred to nitrocellulose membranes (Amer-
sham, Arlington Heights, IL, USA), and the membranesconditions, as confirmed by using an endotoxin-specific
detection kit (Toxicolar system; Seikagaku Co.). Human were blocked in a solution containing 5% bovine serum
albumin, 10 mm Tris-HCl (pH 8.2), and 140 mm NaClserum amyloid A protein (SAA) was kindly provided
by Dr. N. Kubota (Eiken Chemical Ltd., Tochigi, Japan). for 16 hours. The blots were incubated with an anti-
COX-2–specific antibody (IBL Corp.) for two hours atSAA was purified from pooled sera using high concentra-
tions of C-reactive protein by sequential gel filtration as room temperature. The membranes were further incu-
bated with peroxidase-conjugated antirabbit IgG anti-described previously [24]. Rabbit anti-COX-2–specific
antibody was purchased from IBL Co. (Fujioka, Japan). bodies (Amersham) for 60 minutes and were developed
using an enhanced chemiluminescence system (Amer-Anti-b2m–specific antibody was purchased from Dako
Japan (Tokyo, Japan). All other reagents were obtained sham).
from Sigma.
RNA preparation and reverse transcriptase–
polymerase chain reaction (RT-PCR) assaySynovial cell culture
The experimental protocol was approved by the local Total cellular RNA was extracted from synovial fi-
broblasts cultured with or without b2m using guanidiumethics committee, and a signed consent form was ob-
tained from each patient. Synovial tissue samples were thiocyanate and phenol (RNAzol B; Cinna/Bioek Labs
Intl. Inc., Friendswood, TX, USA). First-strand cDNAobtained from patients with rheumatoid arthritis and
osteoarthritis (OA) during synovectomy. The synovial was synthesized by RT at 428C for 45 minutes in a 50
ml reaction mixture containing 1 mg of total RNA andmembranes were minced aseptically and were then disso-
ciated enzymatically with collagenase (4.0 mg/ml; Sigma) MuLV RT (Gibco BRL, Gaithersburg, ND, USA). After
heating at 998C for five minutes for denaturing, followedin RPMI 1640 for four hours at 378C. The obtained
cells were plated on culture dishes and were allowed to by cooling at 58C, the cDNA was used for amplification.
For the PCR reactions, 2 ml of denatured cDNA wasadhere. To eliminate nonadherent cells from synovial
cell preparations, the plated cells were cultured for 18 amplified in a 20 ml final volume with 1 U Taq DNA
polymerase (Gibco BRL), 1 mm of both primers, andhours with RPMI 1640 supplemented with 10% fetal calf
serum at 378C in humidified 5% CO2 in air. The cells Taq polymerase buffer contained 1.5 mm MgCl2 with 1.5
mm of each dNTP. PCR was performed in a thermalwere then washed thoroughly with phosphate-buffered
saline (PBS) solution. Adhering synovial cells were re- cycler (Perkin Elmer Cetus, Foster City, CA, USA) using
a program of 25 cycles at 948C for one minute, 608C formoved by adding trypsin-ethylenediaminetetraacetic
acid and were washed with PBS containing 2% fetal calf one minute, 728C for one minute, followed by a 10-
minute extension at 728C. The amplified products wereserum. The collected synovial cells were used at the third
or fourth passages for subsequent experiments. Synovial subjected to electrophoresis on 1.5% agarose gel.
The specific primers used were as follows: COX-2 [25],cell preparations were less than 1% reactive with mono-
clonal antibodies CD3, CD20, CD68 (Coulter Immunol- 59-TTCAAATGAGATTGTGGGAAAATTGCT-39
(forward primer), 59-AGATCATCTCTGCCTGAGTAogy, FL, USA), and anti-human von Willebrand factor
(Immunotech, Marseille, France), which respectively de- TCTT-39 (reverse primer). The predicted size of the frag-
ment was 301 bp. For b-actin, the primer was 59-GACfine an antigen on mature T lymphocytes, B lymphocytes,
monocytes/macrophages, and vascular endothelial cells. GAGGCCCAGA GCA AGAGAG-39 (forward primer),
59-ACGTACA TGGCTGGGGTGTTG-39 (reverse pri-
COX-2 expression analysis by Western blot mer). The predicted size of the fragment was 284 bp.
The expression of COX-2 was analyzed by the West-
ern blot method as Crofford et al previously described
RESULTS
[20]. For this purpose, the cells were washed with cold
Induction of COX-2 in b2m–treated synovial cellsPBS and lyzed by the addition of a lysis buffer containing
1% nonidet P-40, 50 mm Tris (pH 7.5), 100 mm NaCl, 5 To study whether b2m up-regulates COX-2 biosynthe-
sis in human synovial cells, lysates of synovial cells stimu-mm ethylenediaminetetraacetic acid, 10 mg/ml aprotinin,
and 10 mg/ml leupeptin for 20 minutes at 48C. Insoluble lated with or without b2m (2 mg/ml) were analyzed by
Western blot using anti-COX-2 antibody. In untreatedmaterial was removed by centrifugation at 15,000 3 g
for 15 minutes at 48C. The supernatant was saved, and synovial cells, COX-2 was not detected. However, treat-
ment of synovial cells with b2m for 12 hours resulted inthe protein concentration was determined using a Bio-
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Fig. 3. b2m induces COX-2 protein expression on synovial cells isolated
from osteoarthritis (OA) patients. Synovial cells isolated from OA
patients were cultured with various concentrations of b2m in serum-
free RPMI media for 12 hours. The cells were lysed, and lysates were
analyzed by anti-COX-2 Western blot (lane 1, without b2m; lane 2,
cultured with 0.2 mg/ml of b2m; lane 3, cultured with 2 mg/ml of b2m).
Fig. 1. Western blot demonstrating the COX-2 protein expression in from OA patients. In synovial cells isolated from OA
rheumatoid synovial cells after stimulation with b2-microglobulin (b2m; patients, b2m induced COX-2 expression (Fig. 3). In con-2 mg/ml). Synovial cells were cultured with (lane 2) or without (lane 1)
trast, SAA protein, another amyloid protein, did notb2m (2 mg/ml) in serum-free RPMI media for 12 hours. The cells were
lysed, and lysates were analyzed by anti-COX-2 Western blot as de- induce the COX-2 expression on synovial cells (Fig. 4).
scribed in the Methods section. Prestained molecular markers are shown These results indicate that COX-2 induction is not a
in the far left lane.
generalized effect of amyloid proteins.
To determine whether b2m directly induces COX-2
expression in synovial cells, we performed immunopre-
cipitation analysis using a specific antibody against b2m.
Culture of synovial cells with b2m–containing media
immunoabsorbed by anti-b2 antibody abolished b2m–
mediated COX-2 expression on synovial cells. In con-
trast, immunoabsorption using control rabbit IgG did
not influence b2m–mediated COX-2 expression (data not
shown).
RT–PCR analysis of mRNA for COX-2
To confirm the effects of b2m on COX-2 induction,
we examined COX-2 mRNA in control and b2m–treated
synovial cells by RT–PCR analysis. Reverse transcrip-
Fig. 2. b2m induces COX-2 protein expression on synovial cells. Syno- tion was performed on total RNA from synovial cells
vial cells were cultured with various concentrations of b2m in serum- incubated with 10 U/ml of interleukin-1b for six hours.free RPMI media for 12 hours. The cells were lysed, and lysates were
analyzed by anti-COX-2 Western blot (lane 1, without b2m; lane 2, b-actin (lanes 1 to 5) and COX-2 (lanes 6 to 10) cDNA
cultured with 0.2 mg/ml of b2m; lane 3, cultured with 2 mg/ml of b2m; were amplified by PCR for 19 to 31 cycles. As shown in
lane 4, cultured with 10 mg/ml of b2m). Figure 5A, there was a linear correlation between the
number of cycles (19 to 31), and the yield of PCR produc-
tions of both COX-2 and b-actin, indicating that within
these cycles, our PCR condition can be used for semi-a marked expression of COX-2 polypeptide (Fig. 1). To
quantitation of the respective mRNA.examine the dose response of b2m on COX-2 expression,
The results of COX-2–specific RT–PCR analysis cor-synovial cells were treated with different concentrations
responded well to those of the Western blot analysis.of b2m (0.2 to 10 mg/ml) for 12 hours, and cellular lysates
COX-2 mRNA was not detected in synovial cells underwere analyzed by anti-COX-2 Western blot. As shown
basal conditions. In contrast, stimulation of these cellsin Figure 2, b2m induced COX-2 expression on synovial
with b2m for six hours induced COX-2 mRNA expres-cells in a dose-dependent manner and reached a plateau
sion in a dose-dependent manner. There was no differ-at 2 mg/ml of b2m. We also examined the effects of b2m
on COX-2 expression using the synovial cells isolated ence in the levels of mRNA for b-actin, a control house-
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Fig. 4. Serum amyloid A protein (SAA) did
not induce COX-2 protein expression on syno-
vial cells. Synovial cells were cultured with
various concentrations of SAA in serum-free
RPMI media for 12 hours. The cells were lysed,
and lysates were analyzed by anti-COX-2
Western blot (lane 1, without SAA; lane 2,
cultured with 0.5 mg/ml of SAA; lane 3, cul-
tured with 5 mg/ml of SAA; lane 4, cultured
with 50 mg/ml of SAA; lane 5, cultured with
2 mg/ml of b2m).
Fig. 5. RT–PCR analysis of mRNA for
COX-2 in synovial cells treated with b2m. (A)
Reverse transcription was performed on total
RNA from synovial cells incubated with 10
U/ml of interleukin-1b for six hours as de-
scribed in the Methods section. b-actin (lanes
1–5) and COX-2 (lanes 6–10) cDNA were am-
plified by PCR for 19–31 cycles. Lanes 1–5
(b-actin) correspond to 19, 22, 25, 28, and 31
cycles, and lanes 6–10 (COX-2) correspond to
19, 22, 25, 28, and 31 cycles, respectively. (B)
Synovial cells were treated with various con-
centrations of b2m for six hours. Total RNA
was reverse transcribed following PCR ampli-
fication with primers for COX-2 and b-actin.
Ethidium bromide staining of PCR products
after 25 cycles of amplification and separated
in a 1.5% agarose gel (lane 1, without b2m;
lane 2, cultured with 0.2 mg/ml of b2m; lane 3,
cultured with 2 mg/ml of b2m; lane 4, cultured
with 10 mg/ml of b2m).
keeping gene, between control and b2m–treated synovial in the absence or presence of dexamethasone (1029 to
1027 m) for 12 hours, and cellular lysates were analyzedcells (Fig. 5B).
by anti-COX-2 Western blot. As shown in Figure 6, dexa-
Effects of dexamethasone on COX-2 expression methasone completely inhibited COX-2 polypeptide ex-
pression at physiologically relevant concentrations (moreRecent studies have suggested that glucocorticoids in-
hibit COX-2 mRNA expression by modulating the tran- than 1028 m).
To confirm further the inhibitory effects of dexameth-scription factors that are located upstream of COX-2
gene [26, 27]. We therefore investigated the effects of asone on COX-2 expression, we evaluated the effects of
dexamethasone on b2m–induced COX-2 mRNA expres-dexamethasone on b2m–induced COX-2 expression on
synovial cells. Synovial cells were stimulated with b2m sion using the RT–PCR method. COX-2 mRNA was
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Fig. 6. Effect of dexamethasone on COX-2
protein expression in b2m–stimulated synovial
cells. Synovial cells were treated with b2m (2
mg/ml) in the presence or absence of dexa-
methasone for 12 hours. The cells were lysed,
and lysates were analyzed by anti-COX-2
Western blot.
Fig. 7. Effect of dexamethasone on COX-2
mRNA expression in b2m–stimulated synovial
cells. Synovial cells were treated with b2m (2
mg/ml) in the presence or absence of dexa-
methasone for six hours. Total RNA was re-
verse transcribed following PCR amplification
with primers for COX-2 and b-actin. Ethidium
bromide staining of PCR products after 25
cycles of amplification and separated in a 1.5%
agarose gel.
detected after treatment of synovial cells by b2m (2 mg/ as interleukin-1b enhanced the expression of COX-2 in
synovial cells [20].ml) for six hours. This b2m–mediated COX-2 mRNA
Recent studies have shown that b2m has several bio-induction was inhibited by 1027 to 1028 m of dexametha-
logical functions in a various types of cells. Several inves-sone. This concentration of dexamethasone is similar
tigators provided sufficient evidence indicating that b2mto the concentrations that inhibited COX-2 polypeptide
is involved in the development of osteoarticular diseasessynthesis. No change was noted in 284 bp amplified frag-
[21–24]. We have also recently reported that b2m directlyment of b-actin in synovial cells treated with or without
induces matrix metalloproteinase production from hu-dexamethasone (Fig. 7).
man synovial fibroblasts [22]. In this study, we examined
the impact of b2m on COX-2 expression in human syno-
DISCUSSION vial fibroblasts. These results showed an absence of
Hemodialysis-associated amyloidosis is a serious com- COX-2 protein in human synovial cells under basal con-
plication in patients on long-term dialysis therapy and ditions. However, COX-2 synthesis was markedly in-
may lead to carpal tunnel syndrome, destructive os- creased when these cells were treated with b2m. RT–PCR
teoarthropathy, or cystic bone lesions [5–8]. Amyloid analysis demonstrated that COX-2 mRNA was also en-
deposits are mainly located in joint structures and periar- hanced in b2m–treated synovial cells. It is possible that
ticular bones, and b2m was identified as the major constit- COX-2 expression on synovial cells was induced by con-
uent protein of this unique type of amyloidosis [4, 5]. taminating substances present in the b2m solution, such
However, the pathological role of b2m in the develop- as endotoxin. However, no endotoxin was detected un-
ment of articular and bone lesions is poorly understood. der our experimental culture conditions. Furthermore,
The production of PGs is an important regulatory our results also showed that immunoabsorption of b2m–
mechanism of bone turnover and is involved in bone containing media by anti-b2m–specific antibody abro-
resorption of inflammatory joint disease [28]. COX is an gated the COX-2–inducing activity. These results indi-
important regulatory enzyme in PG biosynthesis [10, 11]. cate that the expression of COX-2 on b2m–treated
COX-1 is considered to be expressed constitutively [14], synovial cells is the direct effect of b2m rather than being
whereas COX-2 is highly inducible by cytokines and mediated by other factors.
growth factors, and is responsible for the enhanced PG Moe et al reported that b2m did not stimulate the
synthesis at inflammatory sites [15–17]. It has been dem- release of prostaglandin E2 (PGE2) from mouse calvariae
onstrated that COX-2 is expressed in human synovial and that b2m–induced bone mineral dissociation is inde-
pendent to PGE2 [29]. This discrepancy between theirtissues, and treatment with inflammatory cytokines such
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